SGMO - Sangamo Therapeutics Inc
IEX Last Trade
0.8473
0.022 2.620%
Share volume: 1,854,331
Last Updated: Fri 30 Aug 2024 09:59:26 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.83
0.02
2.69%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-02-23 | 2023-05-08 | 2023-08-08 | 2023-11-01 | 2024-03-13 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 617.126 M | 593.913 M | 562.509 M | 440.567 M | 325.074 M | 219.697 M | 165.320 M | 128.961 M | |
| Current Assets | 343.120 M | 336.621 M | 300.327 M | 227.087 M | 159.609 M | 147.576 M | 94.328 M | 68.636 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 21.107 M | 18.007 M | 18.223 M | 13.651 M | 12.573 M | 13.715 M | 12.000 M | 12.612 M | |
| Short Term Investments | 21.107 M | 18.007 M | 18.223 M | 13.651 M | 12.573 M | 13.715 M | 12.000 M | 12.612 M | |
| Total Receivables | 6.291 M | 5.046 M | 4.472 M | 8.049 M | 3.935 M | 1.750 M | 1.326 M | 691.000 K | |
| Current Cash | 315.722 M | 313.568 M | 277.632 M | 205.387 M | 143.101 M | 132.111 M | 81.002 M | 54.417 M | |
| Total Non-current Assets | 274.006 M | 257.292 M | 262.182 M | 213.480 M | 165.465 M | 72.121 M | 70.992 M | 60.325 M | |
| Property Plant Equipment | 53.499 M | 55.986 M | 63.531 M | 59.877 M | 60.717 M | 28.436 M | 26.874 M | 22.017 M | |
| Other Assets | 16.113 M | 17.200 M | 17.023 M | 16.242 M | 17.438 M | 14.974 M | 16.627 M | 17.373 M | |
| Intangible Assets | 49.529 M | 46.439 M | 50.729 M | 51.555 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 36.702 M | 34.511 M | 37.552 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 617.126 M | 593.913 M | 562.509 M | 440.567 M | 325.074 M | 219.697 M | 165.320 M | 128.961 M | |
| Total liabilities | 298.845 M | 284.759 M | 267.551 M | 104.957 M | 91.432 M | 84.775 M | 82.433 M | 72.264 M | |
| Total current liabilities | 119.987 M | 122.361 M | 111.711 M | 57.839 M | 53.792 M | 48.482 M | 47.731 M | 40.242 M | |
| Accounts Payable | 13.076 M | 17.380 M | 22.418 M | 19.920 M | 14.837 M | 15.457 M | 15.259 M | 15.468 M | |
| Other liabilities | 131.206 M | 116.953 M | 110.584 M | 3.045 M | 1.267 M | 1.318 M | 1.187 M | 1.205 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 131.206 M | 116.953 M | 110.584 M | 3.045 M | 1.267 M | 1.318 M | 1.187 M | 1.205 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 318.281 M | 309.154 M | 294.958 M | 335.610 M | 233.642 M | 134.922 M | 82.887 M | 56.697 M | |
| Common stock | 148.158 M | 158.042 M | 164.962 M | 168.533 M | 174.325 M | 177.171 M | 177.747 M | 180.342 M | |
| Retained earnings | -1.043 B | -1.097 B | -1.149 B | -1.127 B | -1.242 B | -1.346 B | -1.406 B | -1.455 B |